GSKGlaxoSmithKlineRunning, no new patients
Study of Single Agent Belantamab Mafodotin Versus Pomalidomide Plus Low-dose Dexamethasone (Pom/Dex) in Participants With Relapsed/Refractory Multiple Myeloma (RRMM)
Multiple Myeloma
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 3
- Patients
- 325 (final count)
- Started
- Apr 2, 2020
- Main results expected
- Sep 12, 2022
- Fully finished
- Mar 11, 2027
- Results posted
- Oct 6, 2023
What counts as success
The trial's main goal(s), called the “primary outcome.”
Progression-Free Survival (PFS) Based on Investigator-Assessed Response as Per International Myeloma Working Group (IMWG)
Measured over: Up to 27 months
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT04162210 · record last updated 2026-07-01 · checked 2026-11-09 15:47 UTC